PAVmed Inc. (NASDAQ:PAVM) Short Interest Down 35.1% in April

PAVmed Inc. (NASDAQ:PAVM) was the target of a large decline in short interest during the month of April. As of April 15th, there was short interest totaling 15,238 shares, a decline of 35.1% from the March 31st total of 23,477 shares. Currently, 1.6% of the shares of the stock are short sold. Based on an average trading volume of 10,021 shares, the days-to-cover ratio is currently 1.5 days.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Weiss Ratings restated a “sell (d)” rating on shares of PAVmed in a report on Tuesday, April 21st. Wall Street Zen upgraded PAVmed from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Finally, Ascendiant Capital Markets decreased their target price on PAVmed from $510.00 to $65.00 and set a “buy” rating on the stock in a report on Thursday, April 9th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, PAVmed has a consensus rating of “Hold” and a consensus price target of $65.00.

PAVmed Trading Down 7.0%

Shares of NASDAQ PAVM traded down $0.62 during mid-day trading on Thursday, reaching $8.30. The company had a trading volume of 33,047 shares, compared to its average volume of 11,206. The stock has a market cap of $8.30 million, a PE ratio of -0.36 and a beta of 0.81. The company has a 50-day moving average price of $9.70 and a two-hundred day moving average price of $10.06. PAVmed has a 1-year low of $6.00 and a 1-year high of $28.44.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in PAVmed stock. Jane Street Group LLC increased its holdings in shares of PAVmed Inc. (NASDAQ:PAVM) by 392.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,676 shares of the company’s stock after buying an additional 41,990 shares during the quarter. Jane Street Group LLC owned 0.31% of PAVmed worth $32,000 as of its most recent filing with the Securities and Exchange Commission. 19.93% of the stock is currently owned by institutional investors and hedge funds.

About PAVmed

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.